Logo

Merck KGaA and GSK Discontinue P-II INTR@PID BTC 055 Study of Bintrafusp Alfa as 1L Treatment of Biliary Tract Cancer

Share this

Merck KGaA and GSK Discontinue P-II INTR@PID BTC 055 Study of Bintrafusp Alfa as 1L Treatment of Biliary Tract Cancer

Shots:

  • Merck KGaA discontinues its P-II INTR@PID BTC 055 study evaluating bintrafusp alfa with gemcitabine + cisplatin in patients with locally advanced or metastatic BTC
  • The discontinuation is based on the IDMC’s recommendation following a review of data which concluded that the trial fails to meet the primary objective of OS & no new safety signals were observed
  • Bintrafusp alfa (M7824) is a bifunctional fusion protein targeting TGF-β and PD-L1. The therapy is currently in clinical development under collaboration with GSK

Ref: Merck KGaA | Image: Merck KGaA

Click here to­ read the full press release 

Senior Editor

This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com

Share this article on WhatsApp, LinkedIn and Twitter

Join the PharmaShots family of 12000+ subscribers

I accept the Terms and Conditions